

1 Experimental infection of Mexican free-tailed bats (*Tadarida brasiliensis*) with SARS-CoV-2.

2

3 Hall JS^{1,3}, Hofmeister E¹, Ip HS¹, Nashold SW¹, Leon AE¹, Malavé CM¹, Falendysz EA¹, Rocke
4 TE¹, Carossino M², Balasuriya U², Knowles S¹

5

6 ¹U.S. Geological Survey, National Wildlife Health Center, Madison, Wisconsin

7 ²Louisiana Animal Disease Diagnostic Laboratory and Department of Pathobiological

8 Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana

9 ³Corresponding author

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35 **Abstract.**

36 The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus originated in wild
37 bats from Asia, and as the resulting pandemic continues into its third year, concerns have been
38 raised that the virus will expand its host range and infect North American wildlife species,
39 including bats. Mexican free-tailed bats (*Tadarida brasiliensis*: TABR) live in large colonies in
40 the southern United States, often in urban areas, and as such, could be exposed to the virus from
41 infected humans. We experimentally challenged wild TABR with SARS-CoV-2 to determine the
42 susceptibility, reservoir potential, and population impacts of infection in this species. Of nine
43 bats oronasally inoculated with SARS-CoV-2, five became infected and orally excreted moderate
44 amounts of virus for up to 18 days post inoculation. These five subjects all seroconverted and
45 cleared the virus before the end of the study with no obvious clinical signs of disease. We
46 additionally found no evidence of viral transmission to uninoculated subjects. These results
47 indicate that while TABR are susceptible to SARS-CoV-2 infection, infection of wild
48 populations of TABR would not likely cause mortality. However, the transmission of SARS-
49 CoV-2 from TABR to or from humans, or to other animal species, is a distinct possibility
50 requiring further investigation to better define.

51

52 **Introduction.**

53 As we enter the third year of the severe acute respiratory syndrome coronavirus-2
54 (SARS-CoV-2) pandemic, many unanswered questions remain regarding the ecology of the
55 virus. How the virus interacts with wild species is critical knowledge to obtain, including
56 whether: (1) North American wildlife can act as reservoirs of the virus, (2) the virus can adapt

57 genetically to new hosts and become more virulent, and (3) the virus can affect the health of wild
58 populations, particularly threatened or endangered species.

59 SARS-CoV-2 naturally infects several wild species including captive wild animals. For
60 example, American mink (*Neovison vison*) were infected with SARS-CoV-2 in the United States
61 in proximity to domestic mink farm operations (Shriner et al. 2021). Antibodies to SARS-CoV-2
62 were detected in white-tailed deer (*Odocoileus virginianus*) indicating exposure to the virus
63 (Chandler et al. 2021), and infection was later confirmed in this species (Hale et al. 2022).
64 Captive wild animals in zoos, particularly members of the Felidae family, were infected with the
65 virus (McAloose et al. 2020), and several North American species have experimentally been
66 shown susceptible to the virus, including deer mice (*Peromyscus maniculatus*), striped skunks
67 (*Mephitis mephitis*), and bushy-tailed woodrats (*Neotoma cinerea*) (Bosco-Lauth et al. 2021).

68 Because evidence indicates that SARS-CoV-2 originated in Asian bats (Zhou et al. 2020;
69 Zhou et al. 2021; Wacharapluesadee et al. 2021), concern that the virus could infect North
70 American bat species has been raised, particularly for bat populations under severe threat from
71 another pathogen, *Pseudogymnoascus destructans* (Cheng et al. 2021; Hoyt et al. 2021). Whether
72 North American bats could provide a reservoir of the virus and additional routes of transmission
73 to humans and other susceptible species, as well as any effects of SARS-CoV-2 on populations
74 are important to determine, as are any management measures that could be used to help protect
75 these populations.

76 Big brown bats (*Eptesicus fuscus*) were previously challenged with SARS-CoV-2 and
77 demonstrated resistance to infection (Hall et al. 2021). This species often encounters humans, as
78 they frequently reside in anthropogenic structures, including occupied homes and other
79 buildings. Another common North American bat species, the Mexican free-tailed bat, (TABR:

80 *Tadarida brasiliensis*), resides in very large colonies in the southern United States, often in urban
81 areas. This species is migratory and if susceptible to SARS-CoV-2, could transport the virus
82 to/from Central and South America on their migratory routes. In this study we challenged TABR
83 with SARS-CoV-2 to determine their susceptibility to infection, reservoir potential, the
84 adaptability of the virus to a new potential host, and potential effects of the virus on their
85 populations.

86 **Materials and methods.**

87 ***Virus acquisition and propagation.*** We obtained the SARS-CoV-2 virus (2019-nCoV/USA-
88 WA1/2020) from BEI Resources, National Institute of Allergy and Infectious Diseases (NIAID),
89 National Institutes of Health (NIH) (Manassas, Virginia)The virus was isolated from the first
90 confirmed patient with coronavirus disease 2019 (COVID-19) in the United States (Harcourt et
91 al. 2020). We propagated and quantified the virus in Vero E6 cell culture using standard
92 techniques.

93 ***Animal acquisition and husbandry.*** All husbandry and experimental protocols were
94 approved by the U.S. Geological Survey (USGS) National Wildlife Health Center (NWHC)
95 Institutional Animal Care and Use Committee. Wild TABR were captured in Williamson
96 County, Texas in August 2021. A mixture of adult and juvenile male bats was collected and
97 immediately placed into a temperature-controlled chamber maintained at approximately 20°C.
98 This temperature induced the bats to enter torpor during transport to the NWHC, Madison,
99 Wisconsin.

100 On arrival at the NWHC, the bats were given veterinary examinations and treated
101 topically with selamectin for parasites (Zoetis, Florham Park, New Jersey). The bats were hand
102 fed mealworms (*Tenebrio molito*) supplemented with a vitamin and mineral mixture, and water

103 was provided *ad libitum*. Bats underwent a quarantine and acclimatization period of 30 days
104 prior to commencement of this study during which time the bats learned to feed themselves.

105 ***Pre-inoculation fecal sampling and coronavirus analysis.*** During the acclimatization period, we
106 collected fecal samples from the individual bats to determine the presence of other coronaviruses
107 in these subjects. Each fecal sample was suspended 10% (w/v) in viral transport medium (VTM;
108 Hanks Balanced Salt Solution, 0.05% gelatin, 5% glycerin, 1500 units/ml penicillin, 1500 mg/ml
109 streptomycin, 0.1 mg/ml gentamicin, 1 mg/ml fungizone). Viral RNA was extracted using the
110 MagMax Pathogen RNA/DNA kit (Applied Biosystems, Forest City, California) on a Kingfisher
111 Flex magnetic particle processor according to the manufacturer's instructions. The presence of
112 coronaviruses was determined using methods previously described (Decaro and Larusso, 2020).

113 ***Virus inoculation.*** Experimental inoculations were performed under Biosafety Level-3
114 conditions at the NWHC. We utilized 21 male Mexican free-tailed bats after the acclimatization
115 period and pairs of bats were cohoused in mesh cages. One bat from each of nine bat pairs was
116 inoculated with SARS-CoV-2, and its cagemate was left uninoculated to determine if the virus
117 could be horizontally transmitted between bats. One bat was inoculated and housed individually.
118 The SARS-CoV-2 inoculum dose was 10^5 TCID₅₀/bat and was administered nasally (4 μ l) and
119 orally (6 μ l) using a micropipette. One bat pair was sham inoculated with the same volume of
120 VTM. This technique has been used to inoculate other species with SARS-CoV-2 (Munster et al.
121 2020; Schlottau et al. 2020; Shi et al. 2020; Hall et al. 2021). The inoculum titer was verified by
122 quantitative reverse transcription-polymerase chain reaction (qRT-PCR) as described below and
123 virus viability confirmed in cell culture using Vero E6 cells.

124 ***Animal monitoring and sampling.*** Bats were observed at least twice daily to monitor health
125 status and document development of clinical signs. Just prior to inoculation and every other day

126 thereafter, each bat was weighed, and oropharyngeal and rectal swabs (Puritan Medical Products,
127 Guilford, Maine) were collected and placed in 0.5 ml VTM. On day post-inoculation (DPI) 7 and
128 on DPI 14, bats from one cage (one inoculated bat, one uninoculated) were euthanized, a
129 postmortem examination was conducted, and tissues and blood collected. At the end of the study
130 (DPI 20), all remaining bats were euthanized and postmortem examinations were completed for
131 the control bats and an additional cage pair. Blood was collected for serological analyses from all
132 euthanized bats.

133 **qRT-PCR analyses.** RNA extractions of swab material were performed in 96-well plates using
134 Mag Max-96 AI/ND Viral RNA Isolation Kit (Applied Biosystems, Foster City, California)
135 following the manufacturer's instructions. A positive control sample consisting of a 1:100
136 dilution of the SARS-CoV-2 inoculum used in the study was included with each extraction series
137 to validate successful RNA extraction. qRT-PCR analyses were conducted utilizing the Centers
138 for Disease Control 2019-nCoV N1 primers and probe ([https://www.cdc.gov/coronavirus/2019-
139 ncov/lab/rt-pcr-panel-primer-probes.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)) and AgPath-ID One-Step RT-PCR reagents
140 (Ambion/ThermoFisher, Waltham, Massachusetts). We included a standard curve of serial
141 dilutions of RNA extracted from SARS-CoV-2 virus stock (10^7 TCID₅₀/ml) in each qRT-PCR
142 assay to quantify viral amounts.

143 **Rabies Diagnostics.** Brain tissue was assessed for rabies infection using the direct fluorescent
144 antibody test (DFA). After brain impressions were fixed in acetone, slides were stained with a
145 FITC-labelled monoclonal antibody (mAB) conjugate (Fujirebio U.S. Inc., Malvern,
146 Pennsylvania, USA) and visualized under a fluorescent microscope (Dean et al.1996).

147 **Necropsy and histopathology.** Two animals (inoculated and uninoculated cagemates) were
148 euthanized at DPI 7 (bats 127, 128) and DPI 14 (bats 103, 104), and an additional 2 sets of

149 cagemates at DPI 20 (bats 109, 110, 111, 117), using an overdose of isoflurane with subsequent
150 decapitation. Two uninoculated control animals (102, 108) were also euthanized at DPI 20.
151 These subjects were immediately necropsied after euthanasia and body condition and gross
152 observations were recorded. Portions of the nares, caudal lung, cranial lung, heart, liver, spleen,
153 kidney, small intestine, colon and brain were collected and saved frozen at -80°C for virological
154 analyses. Additional tissue portions were fixed in 10% neutral buffered formalin for histological
155 analysis. For histopathological examination, fixed tissues were processed routinely, sectioned at
156 approximately 5 µm and stained with hematoxylin and eosin at the Wisconsin Veterinary
157 Diagnostic Laboratory (Madison, Wisconsin). At DPI 20, all remaining bats were euthanized,
158 serum was collected, and all bat carcasses were saved frozen. Three bats (118, 123, 124) that
159 were saved frozen and later shown to be infected by swab analysis were subsequently necropsied
160 and sampled.

161 ***SARS-CoV-2-specific immunohistochemistry (IHC)***. For IHC, 4 µm sections of formalin-fixed
162 paraffin-embedded tissue were mounted on positively charged Superfrost® Plus slides and
163 subjected to IHC using an anti-nucleocapsid rabbit monoclonal antibody (HL344, Cell Signaling
164 Technology, Danvers, Massachusetts). IHC was performed using the automated BOND-RXm
165 platform and the Polymer Refine Red Detection kit (Leica Biosystems, Wetzlar, Germany).
166 Following automated deparaffinization, heat-induced epitope retrieval (HIER) was performed
167 using a ready-to-use citrate-based solution (pH 6.0; Leica Biosystems) at 100°C for 20 min.
168 Sections were then incubated with the primary antibody (diluted at 1:1,600 in primary antibody
169 diluent [Leica Biosystems]) for 30 min at room temperature, followed by a polymer-labeled goat
170 anti-rabbit IgG coupled with alkaline phosphatase (30 min). Fast Red was used as the chromogen
171 (15 minutes), and counterstaining was performed with hematoxylin for 5 min. Slides were dried

172 in a 60 °C oven for 30 min and mounted with a permanent mounting medium (Micromount®,
173 Leica Biosystems). Lung sections from a SARS-CoV-2-infected hamster were used as positive
174 assay controls.

175 ***Virus RNA extraction and qRT-PCR from bat tissues.*** Approximately 10 mg of each tissue was
176 macerated in extraction buffer and RNA extracted using the ZYMO Research Quick DNA/RNA
177 Pathogen Miniprep kit (ZYMO Research, Irvine, California) according to the manufacturer's
178 directions. qRT-PCR analyses were performed as described above.

179 ***Antibody detection.*** To detect neutralizing antibodies to SARS-CoV-2, bat sera were screened at
180 a 1:10 dilution using a competitive enzyme linked immunosorbent assay (SARS-CoV-2 sVNT,
181 GenScript, Piscataway, New Jersey) according to the manufacturer's instructions. As directed, a
182 reduction in optical density (OD) of $\geq 30\%$ compared to the mean OD of the negative control
183 was considered positive for the presence of neutralizing antibodies. In addition to the positive
184 control provided in the kit, we used positive guinea pig serum obtained through BEI Resources,
185 NIAID, NIH: Polyclonal Anti-SARS Coronavirus antiserum (Guinea Pig, NR-10361). To
186 determine neutralizing antibody titers from positive sera, samples were two-fold serially diluted
187 and titers recorded as the reciprocal of the end-point dilution where the serum was no longer
188 considered positive.

189 ***Virus recovery and whole genome sequencing.*** Oral swab VTM from Bat 118 DPI 8 was
190 inoculated into Vero E6 cells and incubated at 37 °C, 5% CO₂ for 7 days. The flasks were
191 examined daily for cytopathic effects. Cell lysates collected after three cycles of freezing and
192 thawing were used for RNA extraction and serial passage. Extracted RNA was converted to
193 cDNA with SuperScript IV (ThermoFisher, Waltham, Massachusetts) or Maxima H minus
194 (ThermoFisher, Waltham, Massachusetts) reverse transcriptase according to manufacturer's

195 instructions. Tiled amplicon sequencing by the ARTIC method (Tyson et al. 2020) was
196 performed using Oxford Nanopore Technology's MinION running on a MK1C
197 instrument. Bioinformatic analysis was performed using the CLC Genomics Workbench v22
198 (Qiagen, Redwood City, California) using a publicly available workflow
199 (https://storage.googleapis.com/theiagen-resources/qiagen/SARS-CoV-2_Tutorial.zip).

200 201 **Results.**

202 ***Presence of coronaviruses in Mexican free-tailed bats prior to inoculation.*** RT-PCR analyses
203 of fecal material collected from the TABR prior to virus challenge revealed no evidence of
204 alpha- or betacoronavirus infection, in any subject (Supplemental Table 1).

205 ***Rabies virus infection.*** Prior to SARS-CoV-2 inoculation, one bat exhibited loss of appetite,
206 aggressive behavior towards its cagemate and weight loss over 3-4 days. We euthanized this bat
207 and tested for rabies. It was positive for the presence of rabies virus by DFA, therefore we tested
208 all the remaining TABR after euthanasia and all were negative for the presence of rabies virus
209 (Supplemental Table 1).

210 ***SARS-CoV-2 excretion after experimental inoculation.*** qRT-PCR analysis of oral swabs is
211 shown in Table 1. Of the 10 SARS-CoV-2 inoculated TABR, five (Bats 104, 110, 118, 124, 123)
212 excreted detectable viral RNA. Two additional bats (111, 129) had high cycle threshold (C_t)
213 readings only on the first sampling after inoculation (DPI 2) and likely was detection of residual
214 inoculum. The duration of oral excretion ranged from DPI 6 (Bat 123), up to 18 DPI (Bat 118).
215 The maximum amount of virus detected on an oral swab was 4.82×10^3 TCID₅₀ equivalent/ml (bat
216 118, DPI 4). In contrast to oral excretion, no virus was detected in rectal swabs from any TABR (Table
217 2). The effect of the bat's age on susceptibility was inconclusive as four of the infected bats were adults
218 and one was a juvenile, but the numbers were too small to be reliable.

219 An oral swab from a positive bat (Bat 118 DPI 8) was inoculated into Vero E6 tissue culture to
220 verify viral viability. This resulted in positive virus isolates from the first and third passage that were
221 confirmed to be SARS-CoV-2 by qRT-PCR analyses as described above. Whole genome sequencing of
222 these isolates revealed that they shared the same genetic changes as the WA-1 isolate used as inoculum,
223 when compared to the original Wuhan SARS-CoV-2 isolate. Two additional, consistent changes in both
224 passages of the Bat 118 DPI 8 isolate were found in noncoding regions that were not in the WA-1
225 inoculum isolate. These are shown in Supplemental Table 2.

226 ***Serological analyses.*** SARS-CoV-2 antibodies were detected by competitive Enzyme Linked
227 Immunosorbent Assay (cELISA) in five TABR with percent inhibitions ranging from about 34 –
228 79% (Table 3). These five bats were the same five that were orally excreting virus detected by
229 qRT-PCR (Table 1). These seropositive bat sera were subsequently tested at dilutions from 1:20
230 – 1:80. One serum (110) was positive only at the original 1:10 dilution. Two sera (123, 124)
231 were positive at 1:20 whereas two sera (104, 118) remained positive at 1:40 dilutions.

232 ***Clinical signs of infection, postmortem examination and histopathology.*** Over the three-week
233 course of this study, no overt clinical signs of SARS-CoV-2 disease were observed in 18/21 bats,
234 including the five bats that became infected and were orally excreting virus. These bats
235 maintained or gained weight during the study (Table 4) and appeared healthy. One inoculated bat
236 (127) presented with lethargy, decreased respiratory rate, and increased respiratory effort; and
237 was euthanized on DPI 6, along with its cagemate (128). An additional bat (112) presented with
238 lethargy, obtundation, weight loss, hypersalivation, inability to swallow, and respiratory distress;
239 and was euthanized at DPI 10.

240 Upon further examination, the bat that presented with respiratory difficulty (Bat 127) and
241 its cagemate (128) were in poor or emaciated body condition, respectively, with minimal or no
242 fat stores. Bat 112, euthanized due to respiratory distress and hypersalivation, was in fair body

243 condition. All other bats were in good body condition evidenced by moderate to abundant fat
244 stores. Gross findings included clear nasal discharge (112, 127), red foci or mottling in the lungs
245 (all cases except 127), pulmonary congestion (102-104, 008-011, 117, 118, 128), intestinal pallor
246 (102, 108, 109, 111, 117, 123, 124, 128), small foci of depigmentation of the patagia (103, 108,
247 111, 118, 123, 124, 127) and patagial tears (112, 128).

248 Histopathologic findings included pulmonary congestion, hemorrhage and alveolar
249 collapse (all non-frozen cases), meningeal hemorrhage (103, 104, 111, 112, 127), pulmonary
250 vascular thrombosis (112), large numbers of bacterial rods in bronchial epithelium and cardiac
251 valve and parenchyma (127), pale cardiomyofibers (110, 112, 127), nasal cavity hemorrhage
252 (102, 104, 109, 110, 111, 117, 128), necroulcerative and suppurative pharyngitis with
253 intralesional bacteria (112), exocytosis of neutrophils in nasal turbinate epithelium (104), non-
254 suppurative dermatitis (102, 108, 109, 110, 117), non-suppurative dermal myositis (102),
255 mononuclear cells in hepatic sinusoids (108, 110, 111, 128), trematodes in the lumen of the bile
256 ducts (110, 118) or gall bladder (118, 127), bile duct hyperplasia (110, 118), intestinal
257 nematodiasis (104, 118, 127), intestinal cestodiasis (117, 127), intestinal trematodiasis (118), and
258 intestinal luminal hemorrhage (127). The three additional bats (118, 123, 124) that excreted virus
259 were thawed, necropsies were performed, and tissues were collected. The histologic evaluation
260 of the lungs in these cases was severely hindered by freeze artifact.

261 These histopathologic findings observed for all examined bats were consistent with the
262 euthanasia procedures utilized, parasitism, or bacterial infections, and were not consistent with
263 findings observed in other animals experimentally infected with SARS-CoV-2 (Munster et al.
264 2020; Schlottau et al. 2020; Shi et al. 2020).

265 *Immunohistochemistry for detection of SARS-CoV-2 antigen.* Sections from the rostral nasal
266 cavity, lung, heart, spleen, liver, pancreas, stomach, small and large intestine, and brain from a
267 total of 14 experimentally and mock inoculated bats were subjected to immunohistochemistry for
268 the detection of SARS-CoV-2 antigen. No viral antigen was detected in any of the tissues
269 examined from these bats (Supplemental Table 3).

270 *SARS-CoV-2 in bat tissues.* qRT-PCR analyses of tissues collected from the infected and control
271 bats did not detect viral RNA in any tissue from any of the bats examined (Table 5).

272 **Discussion.**

273 We experimentally challenged Mexican free-tailed bats with SARS-CoV-2. Of the ten
274 inoculated bats, five orally excreted virus for 6-18 days post challenge. These five also mounted
275 an immune response and cleared the virus before the end of the study. Based on these findings
276 we concluded that Mexican free-tailed bats are susceptible to infection by SARS-CoV-2.

277 We found no evidence of transmission between cohoused TABR. Five of the ten (50%)
278 inoculated bats became infected indicating that our inoculum titer (10^5 TCID₅₀/dose) was
279 apparently near the 50% infectious dose for this species. However, the largest amount of virus
280 excreted by infected bats was between 10^3 and 10^4 TCID₅₀ equivalents/ml. Thus, based on these
281 data, contact transmission between TABR would be unlikely.

282 Another possible reason for no transmission between TABR was the way we housed the
283 bats during the challenge study. In the wild, TABR roost in very dense colonies that aggregate in
284 large numbers in natural and anthropogenic structures such as bridges, caves, and culverts. In our
285 study we cohoused two bats, one inoculated and one uninoculated, in cages of approximately 1
286 meter³. This relatively large space did not force the bats to congregate as closely as occurs in

287 natural roosts and thus “social distancing” may have impeded viral transmission. In future
288 challenge studies we plan to adjust the bat housing to help take this factor into account.

289 In addition to the apparent lack of transmission, another observation from this study is
290 that the virus was not excreted via the digestive system. Given the sizes of TABR colonies, large
291 amounts of fecal material accumulate that could potentially become a source of infectious virus.
292 We found no evidence of virus in the digestive tracts or in rectal swabs of any bat, including the
293 infected bats.

294 Another finding was that TABR showed no obvious adverse health effects from SARS-
295 CoV-2 infection. While it is unknown if infected wild bats would have diminished capacity to
296 forage for food, perform maternal care, or other life functions, our findings indicate that TABR
297 populations are likely not at risk from the pandemic.

298 Regardless, an accurate determination of the infectious dose of SARS-CoV-2 in TABR
299 would be an important next study. We do not know if the amounts of virus excreted are enough
300 to infect other mammalian species, including humans or if TABR can be infected with SARS-
301 CoV-2 by exposure to sick humans. Because this species often resides in urban settings, these are
302 important public health and pandemic ecological concerns.

303 We were unable to conduct necropsies and collect tissues from actively infected animals.
304 All bats euthanized for these purposes during the study were not among the infected cohort, and
305 by the end of the study, all infected bats had cleared the virus. Therefore, the qRT-PCR,
306 pathology and histochemistry results from bat tissues were inconclusive.

307 It is generally accepted that SARS-CoV-2 originated in wild horseshoe bats (*Rhinolophus*
308 *sp.*) from China, subsequently transmitted to other host species, and ultimately infected humans,
309 leading to a pandemic (Zhou et al. 2020). The virus also infects at least one other bat species,

310 Egyptian fruit bats, *Rousettus aegyptiacus* (Schlottau et al. 2020). This has raised concerns that
311 the virus could infect North American bats, some of whose populations are under severe pressure
312 from other diseases and from habitat degradation. Hall et al. 2021 previously showed that big
313 brown bats, a species commonly encountered by humans, is resistant to infection by SARS-CoV-
314 2. In this study, however, we demonstrated that TABR, a migratory bat that resides in large
315 colonies, often in urban areas, is susceptible to infection by this virus. Based on the comparative
316 structure of the SARS-CoV-2 cellular receptor, Damas et al. (2020) predicted that TABR were
317 unlikely to become infected with SARS-CoV-2. Thus, it is likely that other factors are involved
318 in mediating susceptibility to this virus. The genetic changes we detected in viral isolates from
319 the swab of one infected bat indicates that mutations can occur rapidly in a new host and that
320 genetic analyses of recovered viral isolates may further inform our understanding of the
321 emergence of novel viral variants. Our findings also indicate that susceptibility of each species to
322 SARS-CoV-2 is independent, and each species would benefit from being examined individually.
323 These results have implications for bat rehabilitators, wildlife biologists, cave recreationists, and
324 the public at large, if they contact Mexican free-tailed bats or enter caves or other environments
325 where bats are roosting.
326 Supporting data are available in Hall et al. (2022) <https://doi.org/10.5066/P9RDA1H6>.

327 **Acknowledgements.**

328 This work was funded by the U.S. Geological Survey's Ecosystems Management Area.
329 M. Carossino received support from the Center for Lung Biology and Disease (CLBD), Center of
330 Biomedical Research Excellence, National Institute of General Medical Sciences of the National
331 Institutes of Health under P20GM130555. We thank Katy Griffin, Jeffrey Messer, Harrison
332 Lamb, Lauren Dycee-Holtz, Rachel Lambert, Carrie Allison Smith, and Casey Hall, for technical

333 contributions. We also thank members of the histopathology and immunohistochemistry section
334 at the Louisiana Animal Disease Diagnostic Laboratory for their assistance. We are particularly
335 indebted to the NWHC Animal Services staff and volunteers, without whose assistance,
336 diligence and hard work this study could not have been accomplished. We are also indebted to
337 the Texas Parks and Wildlife Department for coordinating live bat acquisition. The use of trade,
338 firm, or product names is for descriptive purposes only and does not imply endorsement by the
339 U.S. Government. The authors acknowledge they have no personal financial interests or
340 conflicts of interest with this research article.

341 **References.**

- 342
343 Bosco-Lauth AM, Root JJ, Porter SM, Walker AE, Guilbert L, Hawvermale D, Pepper A,
344 Maison RM, Hartwig AE, Gordy P, Bielefeldt-Ohmann H, Bowen RA. [Peridomestic mammal](#)
345 [susceptibility to severe acute respiratory syndrome coronavirus 2 infection.](#) *Emerg Infect Dis.*
346 2021 Aug;27(8):2073-2080. doi: 10.3201/eid2708.210180.
347
348 Chandler JC, Bevins SN, Ellis JW, Linder TJ, Tell RM, Jenkins-Moore M, Root JJ, Lenocho JB,
349 Robbe-Austerman S, DeLiberto TJ, Gidlewski T, Kim Torchetti M, Shriner SA. SARS-CoV-2
350 exposure in wild white-tailed deer (*Odocoileus virginianus*). *Proc Natl Acad Sci* 2021;
351 118:e2114828118.
352
353 Cheng TL, Reichard JD, Coleman JTH, Weller TJ, Thogmartin WE, Reichert BE, Bennett AB,
354 Broders HG, Campbell J, Etchison K, Feller DJ, Geboy R, Hemberger T, Herzog C, Hicks AC,
355 Houghton S, Humber J, Kath JA, King RA, Loeb SC, Massé A, Morris KM, Niederriter H,
356 Nordquist G, Perry RW, Reynolds RJ, Sasse DB, Scafani MR, Stark RC, Stihler CW, Thomas
357 SC, Turner GG, Webb S, Westrich BJ, Frick WF. The scope and severity of white-nose
358 syndrome on hibernating bats in North America. *Conserv Biol* 2021; 5, 1586-1597. doi:
359 10.1111/cobi.13739
360
361 Damas J, Hughes GM, Keough KC, Painter CA, Persky NS, Corbo M, Hiller M, Koepfli KP,
362 Pfenning AR, Zhao H, Genreux DP, Swofford R, Pollard KS, Ryder OA, Nweeia MT,
363 Lindblad-Toh K, Teeling EC, Karlsson EK, Lewin HA. [Broad host range of SARS-CoV-2](#)
364 [predicted by comparative and structural analysis of ACE2 in vertebrates.](#) *Proc Natl Acad Sci*
365
366
367 *USA.* 2020 Sep 8;117:22311-22322. doi: 10.1073/pnas.2010146117.
368

369 Dean, D.J.; Abelseh, M.K.; Atanasiu, P. *The fluorescent antibody test. Laboratory Techniques*
370 *in Rabies*; Meslin, F.X., Kaplan, M.M., Koprowski, H., Eds.; World Health Organization:
371 Geneva, Switzerland, 1996; pp. 83–93.
372
373 Decaro N, and Larusso A. Novel human coronavirus (SARS-CoV-2): A lesson from animal
374 coronaviruses. *Veterinary Microb.* 2020; 108693.
375
376 Hale VL, Dennis PM, McBride DS, Nolting JM, Madden C, Huey D, Ehrlich M, Grieser J,
377 Winston J, Lombardi D, Gibson S, Saif L, Killian ML, Lantz K, Tell RM, Torchetti M, Robbe-
378 Austerman S, Nelson MI, Faith SA, Bowman AS. [SARS-CoV-2 infection in free-ranging white-](https://doi.org/10.1038/s41586-021-04353-x)
379 [tailed deer.](https://doi.org/10.1038/s41586-021-04353-x) *Nature.* 2022;602:481-486. doi:10.1038/s41586-021-04353-x.
380
381 Hall JS, Knowles S, Nashold SW, Ip H, Leon A, Rocke T, Hofmeister E. Experimental challenge
382 of a North American bat species, big brown bat (*Eptesicus fuscus*), with SARS-CoV-2.
383 *Transboundary Emerg. Dis.* 2021; 68:3443-3452. doi:10.1111/TBED.13949.
384
385 Hall, JS., Hofmeister, EK., Ip, HS., Nashold, SW., Leon, AE., Malavé, CM., Falendysz, EA.,
386 Rocke, TE., Carossino, M., Balasuriya, U., Knowles, S. 2022. Experimental infection of
387 Mexican free-tailed bats (*Tadarida brasiliensis*) with SARS-CoV-2. U.S. Geological Survey data
388 release, <https://doi.org/10.5066/P9RDA1H6>.
389
390 Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, **et al.** Severe acute respiratory
391 syndrome coronavirus-2 from patient with 2019 novel coronavirus disease, United States.
392 *Emerg. Infect. Dis.* 2020; 26:1266-1273.
393
394 Hoyt, J.R., Kilpatrick, A.M. & Langwig, K.E. Ecology and impacts of white-nose syndrome on
395 bats. *Nat Rev Microbiol* 2021; 19, 196–210. <https://doi.org/10.1038/s41579-020-00493-5>
396
397 McAloose D, Laverack M, Wang L, Killian ML, Caserta LC, Yuan F, Mitchell PK, Queen
398 K, Mauldin MR, Cronk BD, Bartlett SL, Sykes JM, Zec S, Stokol T, Ingerman K, Delaney
399 MA, Fredrickson R, Ivančić M, Jenkins-Moore M, Mazingo K, Franzen K, Bergeson
400 NH, Goodman L, Wang H, Fang Y, Olmstead C, McCann C, Thomas P, Goodrich E, Elvinger F,
401 Smith DC, Tong S, Slavinski S, Calle PP, Terio K, Torchetti MK, Diel DG From people
402 to *Panthera*: natural SARS-CoV-2 infection in tigers and lions at the Bronx
403 Zoo. *MBio.* 2020;11:e02220–20. doi: 10.1128/mBio.02220-20.
404
405 Munster VJ, Feldmann F, Williamson BN, van Doremalen N, Pérez-Pérez L, Schulz J, **et al.**
406 Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2.
407 *Nature.* 2020; doi: 10.1038/s41586-020-2324-7.
408
409 Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, et al. Susceptibility of ferrets, cats, dogs,
410 and other domesticated animals to SARS-coronavirus 2. *Science* 2020; 368:1016-1020. doi:
411 10.1126/science.abb7015.
412
413

414 Schlottau K, Rissmann M, Graaf A, Schön J, Sehl J, Wylezich C, Höper D, Mettenleiter TC,
415 Balkema-Buschmann A, Harder T, Grund C, Hoffmann D, Breithaupt A, Beer M. SARS-CoV-2
416 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. *Lancet Microbe*
417 2020; 1:e218-25. doi: 10.1016/S2666-5247(20)30089-6.
418
419 Shriner SA, Ellis JW, Root J, Roug A, Stopak SR, Wiscomb GW, Zierenber, JR, Ip, HS,
420 Torchetti, MK, Deliberto, TJ. SARS-CoV-2 Exposure in Escaped Mink, Utah, USA. *Emerg*
421 *Infect Dis.* 2021; 27:988- 990. doi.org/10.3201/eid2703.204444
422
423 Tyson JR, James P, Stoddart D, Sparks N, Wickenhagen A, Hall G, Choi JH, Lapointe H,
424 Kamelian K, Smith AD, Prystajeky N, Goodfellow I, Wilson SJ, Harrigan R, Snutch TP,
425 Loman NJ, Quick J. Improvements to the ARTIC multiplex PCR method for SARS-CoV-2
426 genome sequencing using nanopore. bioRxiv 2020.09.04.283077;
427 doi: 10.1101/2020.09.04.283077
428
429 Wacharapluesadee S, Tan CW, Maneern P, Duengkae P, Zhu F, Joyjinda Y, Kaewpom T, Chia
430 WN, Ampoot W, Lim BL, Worachotsueptrakun K, Chen VC, Sirichan N, Ruchisrisarod C,
431 Rodpan A, Noradechanon K, Phaichana T, Jantararat N, Thongnumchaima B, Tu C, Crameri G,
432 Stokes MM, Hemachudha T, Wang LF. Evidence for SARS-CoV-2 related coronaviruses
433 circulating in bats and pangolins in Southeast Asia. *Nat Commun* 2021; 12(1):972. doi:
434 10.1038/s41467-021-21240-1.
435
436 Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of
437 probable bat origin. *Nature* 2020; 579:270-73. doi: 10.1038/s41586-020-2012-7.
438
439 Zhou H, Ji J, Chen X, Bi Y, Li J, Wang Q, Hu T, Song H, Zhao R, Chen Y, Cui M, Zhang Y,
440 Hughes AC, Holmes EC, Shi W. Identification of novel bat coronaviruses sheds light on the
441 evolutionary origins of SARS-CoV-2 and related viruses. *Cell* 184 (17), 4380-4391 (2021). doi:
442 10.1016/j.cell.2021.06.
443

444 Table 1. Quantitative RT-PCR analyses of oral swabs from Mexican free-tailed bats inoculated with SARS-CoV-2.
 445

Bat ID	Treatment ¹	Age ²	DPI ³ 0	DPI 2	DPI 4	DPI 6	DPI 8	DPI 10	DPI 12	DPI 14	DPI 16	DPI 18	DPI 20
102	Control	j	No Ct ⁴	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
108	Control	j	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
104	Inoc.	a	No Ct	7.53	2.8X10 ¹	2.32	2.15	1.97	No Ct	No Ct	x ⁵	x	x
103	Trans.	j	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	x	x	x
112	Inoc.	j	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	x	x	x	x	x
113	Trans.	a	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
110	Inoc.	a	No Ct	2.96X10 ³	3.14X10 ³	2.51X10 ²	1.07X10 ³	3.10X10 ²	9.08X10 ¹	3.44	1.37X10 ¹	No Ct	No Ct
117	Trans.	a	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
118	Inoc.	a	No Ct	8.63X10 ²	4.82X10 ³	1.82X10 ³	2.18X10 ³	5.99X10 ¹	4.74X10 ¹	2.08X10 ²	4.74X10 ²	4.30X10 ¹	No Ct
114	Trans.	j	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
120	Inoc.	j	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
121	Trans.	j	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
124	Inoc.	j	No Ct	6.80X10 ²	2.52X10 ²	6.56X10 ²	1.00X10 ³	2.18X10 ¹	No Ct	No Ct	No Ct	No Ct	No Ct
125	Trans.	a	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
111	Inoc.	j	No Ct	6.24	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
109	Trans.	j	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
123	Inoc.	a	No Ct	1.94X10 ²	1.39X10 ²	6.00X10 ¹	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
122	Trans.	j	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
127	Inoc.	a	No Ct	No Ct	No Ct	No Ct	x	x	x	x	x	x	x
128	Trans.	a	No Ct	No Ct	No Ct	No Ct	x	x	x	x	x	x	x
129	Inoc.	j	No Ct	1.38X10 ¹	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct

446 ¹Inoc- Bat oronasally inoculated with 10⁵TCID₅₀ SARS-CoV-2; Trans.-Uninoculated bat cohoused with inoculated bat to determine virus
 447 transmission

448 ²a-adult; j-juvenile

449 ³Day post-inoculation

450 ⁴No Ct- no detectable real-time PCR amplification. Quantities of virus based on standard curve of known virus concentrations and expressed as
 451 TCID₅₀ equivalent/ml

452 ⁵x-Bat euthanized after previous sampling DPI

453 Table 2. Quantitative RT-PCR analyses of rectal swabs from Mexican free-tailed bats inoculated with SARS-CoV-2.
 454

Bat ID	Treatment ¹	DPI ² 0	DPI 2	DPI 4	DPI 6	DPI 8	DPI 10	DPI 12	DPI 14	DPI 16	DPI 18	DPI 20
102	Control	No Ct ³	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
108	Control	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
104	Inoc.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	x ⁴	x	x
103	Trans.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	x	x	x
112	Inoc.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	x	x	x	x	x
113	Trans.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
110	Inoc.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
117	Trans.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
118	Inoc.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
114	Trans.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
120	Inoc.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
121	Trans.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
124	Inoc.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
125	Trans.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
111	Inoc.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
109	Trans.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
123	Inoc.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
122	Trans.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct
127	Inoc.	No Ct	No Ct	No Ct	No Ct	x	x	x	x	x	x	x
128	Trans.	No Ct	No Ct	No Ct	No Ct	x	x	x	x	x	x	x
129	Inoc.	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct	No Ct

455
 456 ¹Inoc- Bat oronasally inoculated with 10⁵TCID₅₀ SARS-CoV-2; Trans.-Uninoculated bat cohoused with inoculated bat to determine virus
 457 transmission

458 ²Day post-inoculation

459 ³No Ct- no detectable real-time PCR amplification. Quantities of virus based on standard curve of known virus concentrations and expressed as
 460 TCID₅₀ equivalents/ml.

461 ⁴x-Bat euthanized after previous sampling DPI

462
463
464
465
466
467

Table 3. Competitive ELISA¹ results of Mexican free-tailed bat sera tested after experimental challenge with SARS-CoV-2.

Bat ID	% Inhibition ²	Results ³				
		1:10	1:20	1:40	1:80	
102*	-2.656	Neg				468
103	14.73	Neg				469
104	62.75	Pos	Pos	Pos	Neg	470
105 ⁴	-157.1	Neg				471
108*	12.66	Neg				472
109	13.49	Neg				473
110	34.32	Pos	Neg	Neg	Neg	474
111	1.690	Neg				475
112	25.28	Neg				476
113	15.21	Neg				477
114	34.25	Neg				478
117	17.42	Neg				479
118	79.30	Pos	Pos	Pos	Neg	
119 ⁴	14.45	Neg				
120	0.862	Neg				
121	14.25	Neg				
122	-24.39	Neg				
123	65.44	Pos	Pos	Neg	Neg	
124	57.30	Pos	Pos	Neg	Neg	
125	-31.63	Neg				
127	-15.07	Neg				
128	28.04	Neg				
129	7.899	Neg				

480
481
482
483
484
485
486
487

¹SARS-CoV-2 sVNT, GenScript, Piscataway, New Jersey

²Inhibition of >30% is positive.

³Two-fold serial dilutions of positive sera

⁴Bats euthanized prior to the study

*Uninoculated controls

488

489 Table 4. Body weights (g) of SARS-CoV-2 inoculated Mexican free-tailed bats.

490

491

<u>Bat ID</u>	<u>Treatment</u>	<u>DPI¹ 0</u>	<u>DPI 2</u>	<u>DPI 4</u>	<u>DPI 6</u>	<u>DPI 8</u>	<u>DPI 10</u>	<u>DPI 12</u>	<u>DPI 14</u>	<u>DPI 16</u>	<u>DPI 18</u>	<u>DPI 20</u>
102	Control	10.19	10.11	11.23	11.27	11.8	12.13	11.78	11.7	13.45	13.13	13.24
108	Control	11.97	11.42	12.1	11.86	12.34	12.48	12.3	12.93	12.31	14.38	14.46
104	Inoculated	11.99	10.56	11.85	12.13	12.9	12.76	12.81	13.11	x ²	x	x
103	Transmission	11.81	10.31	11.3	11.28	11.56	12.12	11.88	12.81	x	x	x
112	Inoculated	11.75	11.97	11.31	9.72	9.26	8.4	x	x	x	x	x
113	Transmission	14.37	13.25	12.84	13.81	14.13	15.08	14.83	15.01	14.67	14.43	14.43
110	Inoculated	16.19	14.34	15.39	15.14	15.36	15.6	16.03	15.09	16.04	16.46	16.66
117	Transmission	12.45	11.26	11.84	11.53	11.83	12.87	12.86	12.18	12.66	13.09	13.13
118	Inoculated	13.45	12.34	12.87	12.56	12.9	13.57	13.7	13.72	13.84	13.91	13.75
114	Transmission	10.85	10.2	10.92	10.66	11.31	11.61	11.7	11.39	11.29	11.27	13.68
120	Inoculated	12.1	10.73	11.71	11.5	11.63	12.14	12.27	12.48	12.9	12.47	12.37
121	Transmission	10.33	11.1	12	11.53	11.55	12.05	11.97	12.04	12.54	12.49	13.11
124	Inoculated	13.25	11.95	12.87	12.52	13.33	13.73	14.05	14.49	14.44	14.09	14.9
125	Transmission	13.07	12.2	12.45	12.16	11.57	12.05	12.19	12.41	12.36	12.56	12.84
111	Inoculated	14.02	13.11	13.15	13.73	13.62	13.92	14.25	13.95	13.98	13.64	13.93
109	Transmission	10.86	11.29	11.14	10.56	10.64	10.99	11.39	12.05	12.14	11.97	12.23
123	Inoculated	11.09	10.45	10.83	10.31	10.62	11.19	11.5	11.78	11.48	11.84	12.12
122	Transmission	9.23	9.45	9.78	10.33	10.6	11.37	11.72	11.57	11.65	11.53	11.71
127	Inoculated	9.13	8.86	9.37	8.69	x	x	x	x	x	x	x
128	Transmission	8.39	8.12	8.07	7.95	x	x	x	x	x	x	x
129	Inoculated	10.4	10.96	10	11.51	10.92	10.7	11.48	12.02	10.74	10.76	11.39

492 ¹Day post-inoculation493 ²x-Bat euthanized after previous sampling DPI

494

495

496

497 Table 5. qRT-PCR analyses of selected tissues from SARS-CoV-2 infected and uninoculated

498 control Mexican free-tailed bats.

499

<u>Tissue</u>	<u>Bat ID</u>						
	<u>102</u> ¹	<u>108</u> ¹	<u>104</u>	<u>110</u>	<u>118</u>	<u>123</u>	<u>124</u>
Brain	NoCt ²	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt
Nares	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt
Lung cranial	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt
Lung, caudal	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt
Heart	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt
Liver	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt
Kidney	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt
Spleen	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt
Small intestine	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt
Colon	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt	NoCt

500 ¹Uninoculated control

501 ²NoCt- no detectable RT-PCR reaction

502 Tissues collected from bats euthanized and necropsied on DPI 20

503

504 Supplemental Table 1. Rabies diagnostic results from Mexican free-tailed bats by direct fluorescent
505 antibody (DFA) and the presence of alpha- or betacoronaviruses prior to initiation of the SARS-CoV-2
506 challenge study.

	<u>Bat ID</u>	<u>Age</u>	<u>Treatment</u>	<u>DFA</u> ²	<u>Coronavirus</u>
507					
508	101	j	None ¹	Pos	Neg
509	105	j	None ¹	Neg	Neg
510	107	j	None ¹	Neg	Neg
511	115	j	None ¹	Neg	Neg
512	119	j	None ¹	Neg	Neg
513	102	j	Control	Neg	Neg
514	108	j	Control	Neg	Neg
515	104	a	Inoculated	Neg	Neg
516	103	j	Transmission	Neg	Neg
517	112	j	Inoculated	Neg	Neg
518	113	a	Transmission	Neg	Neg
519	110	a	Inoculated	Neg	Neg
520	117	a	Transmission	Neg	Neg
521	118	a	Inoculated	Neg	Neg
522	114	j	Transmission	Neg	Neg
523	120	j	Inoculated	Neg	Neg
524	121	j	Transmission	Neg	Neg
525	124	j	Inoculated	Neg	Neg
526	125	a	Transmission	Neg	Neg
527	111	j	Inoculated	Neg	Neg
528	109	j	Transmission	Neg	Neg
529	123	a	Inoculated	Neg	Neg
530	122	j	Transmission	Neg	Neg
531	127	a	Inoculated	Neg	Neg
532	128	a	Transmission	Neg	Neg
533	129	j	Inoculated	Neg	Neg
534					
535					

536
537 ¹None - Bat was euthanized prior to SARS-CoV-2 challenge

538 ²Pos – rabies virus presence in brain tissue; Neg – rabies virus absent in brain tissue or coronavirus
539 absent in fecal material

540

541

542

543 Supplemental Table 2

544 **Variant detection in SARS-CoV-2 isolated from Bat 118, DPI 8.** Genetic changes in the
545 SARS-CoV-2 inoculum strain (USA-WA1/2020; Genbank MN985325) and Bat 118 DPI 8
546 (Genbank OM995890) after one passage in Vero cells compared with the reference strain
547 (Wuhan HU-1; Genbank MN908947). Sample ID- sample name. Reference position- location of
548 genetic variant on Wuhan HU-1 genome. Reference sequence- nucleotide sequence in HU-1.
549 Variant- nucleotide in WA-1 and bat isolate. Count- number of reads covering the variant.
550 Frequency- proportions of reads with variant. AA change- change in amino acid coding affected
551 by variant. Syn.- synonymous
552

553	Sample ID	Reference Position	Reference Sequence	Variant	Count/frequency	AA Change
554	WA-1	8782	C	T	3628/98.45	Syn.
555		28144	T	C	282/96.58	Syn.
556	Bat 118 DPI 8	8782	C	T	3514/98.46	Syn.
557		28144	T	C	311/97.49	Syn.
558		28253	C	T	1509/94.85	Syn.
559		28603	C	T	3928/90.05	Syn.
560						

561 Supplemental Table 3. SARS-CoV-2 antigen distribution in selected tissues from SARS-CoV-2 inoculated and uninoculated control
 562 Mexican free-tailed bats. Bats euthanized, necropsied and tissue samples collected on day post-inoculation (DPI) 7 (bats 127, 128));
 563 DPI 10 (bat 112); DPI 14 (bats 103, 104); and DPI 20 for the remaining bats.

Bat ID

<u>Tissue</u>	<u>102</u> ¹	<u>108</u> ¹	<u>103</u>	<u>104</u> ²	<u>109</u>	<u>110</u> ²	<u>111</u>	<u>112</u>	<u>117</u>	<u>118</u> ²	<u>123</u> ²	<u>124</u> ²	<u>127</u>	<u>128</u>
Brain	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Nares	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Lung	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Heart	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Liver	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Kidney	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Spleen	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Stomach	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Pancreas	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Small intestine	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Colon	None	None	None	None	None	None	None	None	None	None	None	None	None	None

564

¹Uninoculated control

565

²SARS-CoV-2 infected bats

566

567 None: no detectable SARS-CoV-2 nucleocapsid antigen

